Follicular lymphoma (FL) is the second most common lymphoma in the United States and is
characterized by a variable clinical course, disease heterogeneity, and a relapse-and …

Introduction In their lifetime, patients with follicular lymphoma frequently require multiple
treatments, which have improved their survival over the past few decades. The expected …

Background: Current guidelines offer numerous options for initiating therapy in patients with
untreated, advanced stage follicular lymphoma (FL). Selecting among these options that …

Opinion Statement The optimal initial treatment of follicular lymphoma (FL) is not known, and
initial management of patients varies considerably between providers and institutions. The …

Follicular lymphoma (FL) is the most common indolent lymphoma in the United States with
an incidence of 3.4 patients per 100,000 and an estimated 13,960 new patients diagnosed …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma
(NHL). While traditional therapy is not considered curative, most patients experience an …

Background The optimal initial therapy of follicular lymphoma (FL) remains unclear. The
aims of this study were to compare primary treatment strategies and assess the impact of …

Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options.
Despite the abundance of efficacious treatment modalities, there is no universally agreed …